Literature DB >> 21544815

Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.

Sabine Ottinger1, Anne Klöppel, Vanessa Rausch, Li Liu, Georgios Kallifatidis, Wolfgang Gross, Martha-Maria Gebhard, Franz Brümmer, Ingrid Herr.   

Abstract

Cancer stem cells (CSCs) are suggested as reason for resistance of tumors toward conventional tumor therapy including pancreatic and advanced prostate cancer. New therapeutic agents are urgently needed for targeting of CSCs. Marine sponges harbor novel and undefined compounds with antineoplastic activity but their potential to eliminate CSC characteristics is not examined so far. We collected 10 marine sponges and one freshwater sponge by diving at the seaside and prepared crude methanolic extracts. The effect to established pancreatic and prostate CSC lines was evaluated by analysis of apoptosis, cell cycle, side population, colony and spheroid formation, migratory potential in vitro and tumorigenicity in vivo. While each sponge extract at a 1:10 dilution efficiently diminished viability, Crambe crambe marine sponge extract (CR) still strongly reduced viability of tumor cells at a dilution of 1:1,000 but was less toxic to normal fibroblasts and endothelial cells. CR inhibited self-renewal capacity, apoptosis resistance, and proliferation even in gemcitabine-selected pancreatic cancer cells with acquired therapy resistance and enhanced CSC characteristics. CR pretreatment of tumor cells diminished tumorigenicity of gemcitabine-resistant tumor cells in mice and totally abolished tumor take upon combination with gemcitabine. Our data suggest that CR contains substances, which render standard cancer therapy more effective by targeting of CSC characteristics. Isolation of bioactive metabolites from CR and evaluation in mice are required for development of new CSC-specific chemotherapeutic drugs from a marine sponge.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544815     DOI: 10.1002/ijc.26168

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Authors:  Amir Avan; Francesco Crea; Elisa Paolicchi; Niccola Funel; Elena Galvani; Victor E Marquez; Richard J Honeywell; Romano Danesi; Godefridus J Peters; Elisa Giovannetti
Journal:  Mol Cancer Ther       Date:  2012-05-23       Impact factor: 6.261

2.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Authors:  Jianguo Wen; Wenjing Tao; Isere Kuiatse; Pei Lin; Yongdong Feng; Richard J Jones; Robert Z Orlowski; Youli Zu
Journal:  Int J Cancer       Date:  2014-07-23       Impact factor: 7.396

Review 3.  Embryonic stem cell factors and pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Luis Bujanda; Daniel D Billadeau; Jin-San Zhang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 4.  Advanced prostate cancer--a case for adjuvant differentiation therapy.

Authors:  Jayant K Rane; Davide Pellacani; Norman J Maitland
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

5.  Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

Authors:  Kazuhiro Yoshida; Shusuke Toden; Preethi Ravindranathan; Haiyong Han; Ajay Goel
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

Review 6.  Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.

Authors:  Shruti Mishra; Sumit S Verma; Vipin Rai; Nikee Awasthee; Srinivas Chava; Kam Man Hui; Alan Prem Kumar; Kishore B Challagundla; Gautam Sethi; Subash C Gupta
Journal:  Cell Mol Life Sci       Date:  2019-03-16       Impact factor: 9.261

7.  Targeting cancer stem cells: a new therapy to cure cancer patients.

Authors:  Yapeng Hu; Liwu Fu
Journal:  Am J Cancer Res       Date:  2012-04-28       Impact factor: 6.166

8.  Mechanism of cytotoxic action of crambescidin-816 on human liver-derived tumour cells.

Authors:  J A Rubiolo; H López-Alonso; M Roel; M R Vieytes; O Thomas; E Ternon; F V Vega; L M Botana
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  Culture-dependent and independent approaches for identifying novel halogenases encoded by Crambe crambe (marine sponge) microbiota.

Authors:  Başak Öztürk; Lenny de Jaeger; Hauke Smidt; Detmer Sipkema
Journal:  Sci Rep       Date:  2013-09-27       Impact factor: 4.379

Review 10.  Development of Marine-Derived Compounds for Cancer Therapy.

Authors:  Weimin Zuo; Hang Fai Kwok
Journal:  Mar Drugs       Date:  2021-06-15       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.